Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic
-
- Toshifumi Tada
- Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan
-
- Takashi Kumada
- Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan
-
- Hidenori Toyoda
- Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan
-
- Kunihiko Tsuji
- Center for Gastroenterology Teine Keijinkai Hospital Sapporo Japan
-
- Atsushi Hiraoka
- Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan
-
- Kojiro Michitaka
- Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan
-
- Akihiro Deguchi
- Department of Gastroenterology Kagawa‐Rosai Hospital Marugame Japan
-
- Toru Ishikawa
- Department of Gastroenterology Saiseikai Niigata Daini Hospital Niigata Japan
-
- Michitaka Imai
- Department of Gastroenterology Saiseikai Niigata Daini Hospital Niigata Japan
-
- Hironori Ochi
- Hepato‐Biliary Center Matsuyama Red‐Cross Hospital Matsuyama Japan
-
- Koji Joko
- Hepato‐Biliary Center Matsuyama Red‐Cross Hospital Matsuyama Japan
-
- Noritomo Shimada
- Department of Gastroenterology Otakanomori Hospital Kashiwa Japan
-
- Kazuto Tajiri
- Department of Gastroenterology Toyama University Hospital Toyama Japan
-
- Masashi Hirooka
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Matsuyama Japan
-
- Yohei Koizumi
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Matsuyama Japan
-
- Yoichi Hiasa
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Matsuyama Japan
-
- Junko Tanaka
- Department of Epidemiology, Infectious Disease Control, and Prevention Hiroshima University Institute of Biomedical and Health Sciences Hiroshima Japan
書誌事項
- 公開日
- 2019-02-27
- 資源種別
- journal article
- 権利情報
-
- http://onlinelibrary.wiley.com/termsAndConditions#vor
- DOI
-
- 10.1111/jgh.14564
- 公開者
- Wiley
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Aim</jats:title><jats:p>Albumin–bilirubin (ALBI) grade was developed as a new method to assess hepatic function. Sorafenib has been confirmed to be effective in improving survival in patients with advanced hepatocellular carcinoma (HCC). In this study, we investigated the impact of ALBI grade <jats:italic>versus</jats:italic> Child–Pugh classification on survival in HCC patients who received sorafenib.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A total of 567 patients with advanced HCC who received sorafenib were included. We analyzed survival based on Child–Pugh classification or score and ALBI grade or score. We also compared the ability of ALBI and Child–Pugh scores to predict survival using time‐dependent receiver operating characteristic analysis.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Cumulative survival rates at 90, 180, 360, and 720 days were 84.1%, 66.6%, 47.0%, and 23.3%, respectively. Median survival was 316 days (95% confidence interval, 279–377). Both Child–Pugh classification and ALBI grade were independently associated with overall survival in multivariate analyses. In addition, overall survival differed significantly between patients with ALBI grades 1 and 2 (hazard ratio, 1.44; 95% confidence interval, 1.09–1.92, <jats:italic>P</jats:italic> = 0.011) among patients with a Child–Pugh score of 5. Time‐dependent receiver operating characteristic analysis showed that ALBI score predicted overall survival better than Child–Pugh score.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Albumin–bilirubin grade is a better predictor of survival in patients with advanced HCC who received sorafenib therapy than Child–Pugh classification.</jats:p></jats:sec>
収録刊行物
-
- Journal of Gastroenterology and Hepatology
-
Journal of Gastroenterology and Hepatology 34 (6), 1066-1073, 2019-02-27
Wiley
